Qu Biologics Announces Initial Results in Randomized, Placebo-Controlled Crohn’s Disease Clinical Trial
Vancouver, British Columbia – March 21, 2016 – Qu Biologics Inc., an immunotherapy company developing Site Specific Immunomodulators (SSIs) for cancer and other inflammatory diseases, announced
Qu Biologics Completes Enrollment of Randomized Clinical Trial in Crohn’s Disease
Vancouver, British Columbia – November 24, 2015 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the
Qu Biologics Begins Phase 2 Clinical Trial in Ulcerative Colitis
Vancouver, British Columbia – July 28, 2015 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the
Qu Biologics Opens Clinical Trial Sites in Edmonton and Toronto
Vancouver, British Columbia – April 24, 2015 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body’s normal immune function
Qu Biologics Welcomes Gastroenterologist Dr. Remo Panaccione to IBD Advisory Team
Vancouver, British Columbia – December 4, 2014 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the
Qu Biologics’ Crohn’s Disease Clinical Trial Completes Independent Safety Review
Vancouver, British Columbia – October 29, 2014 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body’s immune system,
Qu Biologics to Present in Victoria, Kamloops, Calgary and Edmonton
Crohn’s and Colitis Canada – Western Canada invites you to an evening of inspiration and learning. Dr. Hal Gunn, immune system expert and founder of Qu Biologics will present “The Immune
Qu Biologics Presents Crohn’s Disease Compassionate Use Results at DDW
Vancouver, British Columbia – April 28, 2014 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s immune system,
Qu Biologics Opens Crohn’s Disease Clinical Trial to U.S. Participants
Vancouver, British Columbia – February 18, 2014 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s innate
FREE SEMINAR: Microbial involvement in Crohn’s disease
Qu Biologics is pleased to welcome microbiology expert Dr. Brian Coombes to Vancouver to give a seminar on his recently published research in Nature Communications demonstrating that infection of